Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.73 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.73 |
| ▸ | F2 | P00734 | 4/20 | 0.72 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.71 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.71 |
| ▸ | CALCR | P30988 | 4/20 | 0.70 |
| ▸ | NPY2R | P49146 | 9/20 | 0.66 |
| ▸ | NPY4R | P50391 | 8/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.66 |
| ▸ | NPY1R | P25929 | 7/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351932 | 0.95 | CRHR1 (0.74) | HCRTR1HCRTR2F2CRHR1CRHR2 | |
| SCHEMBL31362091 | 0.94 | CRHR1 (0.69) | HCRTR1HCRTR2F2CRHR1CRHR2 | |
| SCHEMBL29440046 | 0.93 | CRHR1 (0.77) | HCRTR1HCRTR2F2CRHR1CRHR2 | |
| Neuropeptide-Y SCHEMBL31042464 | 0.91 | NPY2R (0.73) | HCRTR1HCRTR2CRHR1CRHR2CALCR | |
| SCHEMBL29526997 | 0.90 | NPY2R (0.72) | HCRTR1HCRTR2CALCRNPY2RNPY4R | |
| Human Neuropeptide Y SCHEMBL29523348 | 0.90 | CALCR (0.72) | CRHR1CRHR2CALCRNPY2RNPY4R | |
| SCHEMBL29496288 | 0.90 | NPY2R (0.74) | CRHR1CRHR2CALCRNPY2RNPY4R | |
| SCHEMBL29571016 | 0.89 | NPY2R (0.70) | CRHR1CRHR2CALCRNPY2RNPY4R | |
| Human Neuropeptide Y SCHEMBL29523253 | 0.89 | NPY2R (0.70) | CRHR1CRHR2CALCRNPY2RNPY4R | |
| SCHEMBL29496391 | 0.88 | NPY2R (0.72) | CALCRNPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4074729-B1 | AMYLIN ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-04-15 | — | — | EP | claimed |
| WO-2023224431-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GERIATRIC DISEASES COMPRISING NEURAL STEM CELLS DERIVED FROM THREE-DIMENSIONAL HYPOTHALAMUS ORGANOID AND USE THEREOF | 코아스템켐온 주식회사 | 2023-11-23 | — | — | WO | claimed |
| WO-2023178277-A1 | CLOSED BIPOLAR ELECTRODE BASED BIOSENSORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-09-21 | — | — | WO | claimed |
| EP-3443085-B1 | GENOME EDITING OF HUMAN NEURAL STEM CELLS USING NUCLEASES | BOCO SILICON VALLEY INC (US) | 2022-09-14 | — | — | EP | claimed |
| EP-3919116-B1 | SYSTEMS FOR REDUCING NEURAL ACTIVITY IN AN ORGAN OF A SUBJECT | DIGMA MEDICAL LTD (IL) | 2025-06-04 | — | — | EP | disclosed |
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240043839-A1 | IHH AS A BIOMARKER AND THERAPEUTIC TARGET FOR NONALCOHOLIC STEATOHEPATITIS (NASH) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-02-08 | — | — | US | disclosed |
| WO-2023224431-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GERIATRIC DISEASES COMPRISING NEURAL STEM CELLS DERIVED FROM THREE-DIMENSIONAL HYPOTHALAMUS ORGANOID AND USE THEREOF | 코아스템켐온 주식회사 | 2023-11-23 | — | — | WO | disclosed |
| WO-2023178277-A1 | CLOSED BIPOLAR ELECTRODE BASED BIOSENSORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-09-21 | — | — | WO | disclosed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | PALATIN TECHNOLOGIES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4100040-A1 | DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220363719-A1 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-20220347264-A1 | USE OF FKBP-L POLYPEPTIDES AND NUCLEIC ACIDS FOR THE TREATMENT OF OBESITY | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2022-11-03 | — | — | US | disclosed |
| US-20220324909-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3528831-B1 | USE OF FKBP-L POLYPEPTIDES AND NUCLEIC ACIDS FOR THE TREATMENT OF OBESITY | ROYAL COLLEGE SURGEONS IRELAND (IE) | 2022-09-21 | — | — | EP | disclosed |
| US-20220242912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-08-04 | — | — | US | disclosed |
| US-11376308-B2 | Use of FKBP-L polypeptides and nucleic acids for the treatment of obesity | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2022-07-05 | — | — | US | disclosed |
| US-11332497-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2022081645-A1 | IHH AS A BIOMARKER AND THERAPEUTIC TARGET FOR NONALCOHOLIC STEATOHEPATITIS (NASH) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | HCRTR1 3338/4885HCRTR2 3087/4885F2 3354/4885 |
| US-20220363719-A1 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | MC1R, NPY1R, MC3R | HCRTR1 21/4885HCRTR2 74/4885F2 919/4885 |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | MC1R, MC3R, MC5R | HCRTR1 37/4885HCRTR2 41/4885F2 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.